FDA: Janssen Pharma - Pleads Guilty - To Pay Over $1.6 billion - re: Risperdal

• FDA cGMP QSR GMP Training - online training courses by SkillsPlus International Inc.

Updated August 29, 2020

The link in the original post broke.

You might also be interested in the DOJ's statement about the issue:

Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations
Allegations Include Off-label Marketing and Kickbacks to Doctors and Pharmacists - Justice.gov

- - -  the original post follows below  - - -

Press Announcements > FDA: Janssen Pharmaceuticals, Inc. to plead guilty and pay over $1.6 billion to resolve allegations of misbranding and filing false claims for its schizophrenia drug Risperdal:

"U.S. Department of Justice today announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., (JPI) of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce. A Johnson & Johnson Company, JPI must also pay $1.25 billion under a separate civil settlement concerning the same drug. The combined criminal plea and civil settlement agreement related to Risperdal totals more than $1.67 billion."

Return Home: The Health, Drug, Prescription, and GMP Supersite Blog